Lebwohl M, Warren RB, Imafuku S, Bagel J, Armstrong AW, Passeron T, Banerjee S, Colombo MJ, Scharnitz T, Hoyt K, Thaci D, Blauvelt A. Deucravacitinib Long-Term Efficacy Through 4 years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program. J of Skin [Internet]. 2024Jul.23 [cited 2024Jul.23];8(4):s408. Available from: https://jofskin.org/index.php/skin/article/view/2872